Moderna
Moderna’s Mpox Vaccine Shows Superior Efficacy in Preclinical Study Compared to Approved Version
Moderna, Mpox vaccine, Preclinical study, Superior efficacy, Approved version
FDA Approves Updated COVID-19 Vaccines from Pfizer and Moderna for Enhanced Protection
COVID-19 vaccines, FDA approval, mRNA vaccines, Pfizer, Moderna, updated vaccines, KP.2 variant, JN.1 lineage, emergency use authorization, vaccination guidelines.
Impact of New CDC Guidelines on RSV Vaccine Makers
RSV vaccine, CDC guidelines, vaccine makers, Moderna, Pfizer, GSK, Guillain-Barré syndrome, vaccination recommendations
Flagship’s Noubar Afeyan on Uncertainty, AI, and the Future of Biotechnology
, Noubar Afeyan, Flagship Pioneering, Biotechnology, Artificial Intelligence (AI), Uncertainty, Innovation, Future of Biotech, Moderna, Venture Capital,
Moderna Secures $176 Million BARDA Award for Bird Flu Vaccine Development
Moderna, BARDA, Bird Flu, Vaccine Development, mRNA Technology, Pandemic Preparedness
Moderna’s Combination Flu and COVID-19 Vaccine Shows Promising Results in Late-Stage Trial
Moderna, flu vaccine, COVID-19 vaccine, combination vaccine, mRNA-1083, late-stage trial, immune response, influenza, SARS-CoV-2, respiratory viruses
Moderna and Merck’s Cancer Vaccine Shows Promising Results in Combination with Keytruda
Moderna, Merck, Cancer Vaccine, Keytruda, Melanoma, mRNA Technology, ASCO, FDA, Rare Disease, START Pilot Program
FDA Approves Moderna’s RSV Vaccine, Marking Its Second Commercial Product
Moderna, RSV Vaccine, FDA Approval, mRNA Technology, Respiratory Syncytial Virus, COVID-19, Spikevax, mRESVIA
Moderna Secures Victory in EU Patent Dispute with Pfizer-BioNTech over COVID-19 Vaccine
Moderna, Pfizer, BioNTech, EU, patent dispute, COVID-19 vaccine, mRNA technology, European Patent Office (EPO), intellectual property rights, pharmaceutical industry.
Moderna’s Diversification Strategy Hindered by FDA Delay in RSV Vaccine Review
Moderna, FDA, RSV vaccine, diversification strategy, vaccine review, delay